It is not surprising that many GPCR-targeting drugs are under investigation or in clinical trials for the treatment of NAFLD/NASH since they are critically involved in the early pathogenesis of various metabolic diseases [179]. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.